Initiator Pharma A/S, a clinical-stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous systems. The company is developing Pudafensine, a monoamine reuptake inhibitor that has completed a Phase IIb clinical trial primarily targeting the dopamine system for the treatment of treatment-resistant organic erectile dysfunction; a Phase IIa trial for the treatment of vulvodynia; and preclinical development for the treatment of female sexual dysfunction (FSD). It is also developing IP2018, a monoamine reuptake inhibitor that is in Phase IIb for the treatment of psychogenic erectile dysfunction and in preclinical development for the treatment of FSD, as well as IP2016, which is in preclinical development for the treatment of depression and pain. The company was incorporated in 2016 and is headquartered in Copenhagen, Denmark.…
Initiator Pharma (STO: INIT) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1 employees.
The shares were at 2.500 SEK on 20 November 2026, down 9.1% over 52 weeks. Its 52-week range is 1.665 SEK to 3.650 SEK: the price is 31.5% below the high and 50.2% above the low.
Its market capitalisation is 171.13M SEK.
Initiator Pharma reports return on equity of -46.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 7.40M DKK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 5.155 SEK is 106.2% above the current price.
No upcoming events tracked.